Given parallels between the pro-nociceptive effects of VEGF-A in rodents [4; 58] and humans [23; 58] and clinical findings demonstrating increased VEGF-A levels in bronchial alveolar lavage fluid from COVID-19 patients [47] coupled with substantially lower levels in the sera of asymptomatic individuals compared to symptomatic patients [30], a secondary question was to test whether Spike protein could confer analgesia. The gene discussed is VEGFA; the disease is COVID-19.